There was an initial transient increase of the B cell pool in subjects treated with single or multiple doses of blisibimod, but this was not statistically significant and was similar to previous findings in SLE patients treated with the BAFF antagonists atacicept [29, 30] and belimumab [31, 32]. Here, TNFSF13B is linked to systemic lupus erythematosus.